Amgen CEO sees higher sales in 2012 Summary Box: Amgen CEO sees higher sales in 2012 Jan 9 05:44 PM US/Eastern RISING TIDE: Robert Bradway, on deck as Amgen's next CEO, predicts newer products and expanding operations into more countries to bring higher revenue down the road. MOMENTUM: Positive developments include last year's purchase of a cancer vaccine developer and moves to protect long-term sales of top seller Enbrel, for psoriasis and rheumatoid arthritis, and anemia treatment Epogen. MANAGEMENT MOVES: Along with Bradway, Amgen has appointed new heads of commercial operations and research and development. It also plans more share buybacks.